Background and Purpose-Abnormalities of dermal connective tissue have been detected in patients with spontaneous cervical artery dissections (sCAD), suggesting an underlying structural defect of the arterial wall. ␣ 1 -Antitrypsin (A1-AT) is a circulating serine proteinase inhibitor of proteolytic enzymes that helps to maintain the integrity of elastic and collagen fibers. Methods-To test the hypothesis that moderate deficiency of A1-AT may be a risk factor for sCAD, 22 cases with sCAD and 113 controls were included in the study. Key Words: alpha 1-antitrypsin Ⅲ aneurysm, dissecting Ⅲ risk factors G enetic and environmental factors have been proposed in the pathogenesis of spontaneous cervical artery dissections (sCAD). 1 Abnormalities of dermal connective tissue have been detected in most patients with sCAD, suggesting an underlying structural defect of the arterial wall. 2 In such patients, damaged collagen and elastic fibers might predispose to arterial wall rupture in points of weakness after mechanical stress. 1,2 The presence and intensity of vascular risk factors (smoking, homocysteine, hypertension, oral contraceptives, infections, etc) might explain the sCAD cluster at about the middle of life despite the congenital structural defect of the vessel. Genetically determined alterations of the extracellular matrix may be an important field to investigate the genesis of sCAD. 2,3 ␣ 1 -Antitrypsin (A1-AT) is a circulating serine proteinase inhibitor of proteolytic enzymes that contributes to the maintenance of the integrity of connective tissues. Deficiency of A1-AT may result in degradation of the arterial wall through inadequate protection against the proteolytic effect of elastase and collagenase. 4,5 A1-AT deficiency is a genetic and systemic disorder characterized not only by lung and liver disease but also by vascular manifestations, including sCAD, fibromuscular dysplasia, or aneurysms. 4,5 However, A1-AT deficiency ranges from severe forms with very low circulating levels (10% of normal) in homozygous patients to other forms with moderately low concentrations (60% to 70% of normal) in heterozygous patients. 4,5 To evaluate whether moderate deficiency of A1-AT may be a risk factor for sCAD, we performed a prospective case-control study comparing plasma levels of A1-AT in consecutive patients with sCAD and controls.
Results-Patients
MethodsWe examined 22 consecutive patients with stroke and sCAD confirmed by conventional angiography or MR angiography and cervical MRI. Controls (nϭ113) were stroke patients without sCAD admitted during the same period of time who had complete neurovascular studies (carotid ultrasounds, MR angiography, or conventional arteriography).We recorded demographic data and presence of vascular risk factors. A blood sample was taken at least 2 weeks after stroke onset in cases and controls to avoid the effect of the acute-phase response on plasma protein levels. A1-AT determinations were performed at the hospital laboratory following a standard immune nephelometric technique. Estab...